1050 related articles for article (PubMed ID: 37005490)
21. The cGAS-STING signaling in cardiovascular and metabolic diseases: Future novel target option for pharmacotherapy.
Oduro PK; Zheng X; Wei J; Yang Y; Wang Y; Zhang H; Liu E; Gao X; Du M; Wang Q
Acta Pharm Sin B; 2022 Jan; 12(1):50-75. PubMed ID: 35127372
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer models: Engineering the tumor microenvironment.
Bahcecioglu G; Basara G; Ellis BW; Ren X; Zorlutuna P
Acta Biomater; 2020 Apr; 106():1-21. PubMed ID: 32045679
[TBL] [Abstract][Full Text] [Related]
23. cGAS/cGAMP/STING signal propagation in the tumor microenvironment: Key role for myeloid cells in antitumor immunity.
Mekers VE; Kho VM; Ansems M; Adema GJ
Radiother Oncol; 2022 Sep; 174():158-167. PubMed ID: 35870728
[TBL] [Abstract][Full Text] [Related]
24. Integration of chemokine signaling with non-coding RNAs in tumor microenvironment and heterogeneity in different cancers.
Arora S; Khan S; Zaki A; Tabassum G; Mohsin M; Bhutto HN; Ahmad T; Fatma T; Syed MA
Semin Cancer Biol; 2022 Nov; 86(Pt 2):720-736. PubMed ID: 35257861
[TBL] [Abstract][Full Text] [Related]
25. Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC.
Li K; Gong Y; Qiu D; Tang H; Zhang J; Yuan Z; Huang Y; Qin Y; Ye L; Yang Y
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002188
[TBL] [Abstract][Full Text] [Related]
26. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.
Peters S; Paz-Ares L; Herbst RS; Reck M
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858709
[TBL] [Abstract][Full Text] [Related]
27. Beyond Cell Motility: The Expanding Roles of Chemokines and Their Receptors in Malignancy.
Morein D; Erlichman N; Ben-Baruch A
Front Immunol; 2020; 11():952. PubMed ID: 32582148
[TBL] [Abstract][Full Text] [Related]
28. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
Gulley JL; Schlom J; Barcellos-Hoff MH; Wang XJ; Seoane J; Audhuy F; Lan Y; Dussault I; Moustakas A
Mol Oncol; 2022 Jun; 16(11):2117-2134. PubMed ID: 34854206
[TBL] [Abstract][Full Text] [Related]
29. Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy.
Qiu Q; Lin Y; Ma Y; Li X; Liang J; Chen Z; Liu K; Huang Y; Luo H; Huang R; Luo L
Front Immunol; 2020; 11():612202. PubMed ID: 33488618
[TBL] [Abstract][Full Text] [Related]
30. The regulation of immune checkpoints by the hypoxic tumor microenvironment.
Hu M; Li Y; Lu Y; Wang M; Li Y; Wang C; Li Q; Zhao H
PeerJ; 2021; 9():e11306. PubMed ID: 34012727
[TBL] [Abstract][Full Text] [Related]
31. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
[TBL] [Abstract][Full Text] [Related]
32. Chemokine-Cytokine Networks in the Head and Neck Tumor Microenvironment.
Nisar S; Yousuf P; Masoodi T; Wani NA; Hashem S; Singh M; Sageena G; Mishra D; Kumar R; Haris M; Bhat AA; Macha MA
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925575
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms and pathways of innate immune activation and regulation in health and cancer.
Cui J; Chen Y; Wang HY; Wang RF
Hum Vaccin Immunother; 2014; 10(11):3270-85. PubMed ID: 25625930
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity.
Yano H; Andrews LP; Workman CJ; Vignali DAA
Immunology; 2019 Jul; 157(3):232-247. PubMed ID: 31087644
[TBL] [Abstract][Full Text] [Related]
35. The tumor microenvironment: shaping cancer progression and treatment response.
Desai SA; Patel VP; Bhosle KP; Nagare SD; Thombare KC
J Chemother; 2024 Jan; ():1-30. PubMed ID: 38179655
[TBL] [Abstract][Full Text] [Related]
36. Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy.
Yu Y; Bogdan M; Noman MZ; Parpal S; Bartolini E; Van Moer K; Kleinendorst SC; Bilgrav Saether K; Trésaugues L; Silvander C; Lindström J; Simeon J; Timson MJ; Al-Hashimi H; Smith BD; Flynn DL; Alexeyenko A; Viklund J; Andersson M; Martinsson J; Pokrovskaja Tamm K; De Milito A; Janji B
Mol Oncol; 2024 Mar; ():. PubMed ID: 38506049
[TBL] [Abstract][Full Text] [Related]
37. Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy.
de Looff M; de Jong S; Kruyt FAE
Front Immunol; 2019; 10():1530. PubMed ID: 31333662
[TBL] [Abstract][Full Text] [Related]
38. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
39. High-throughput microfluidic 3D biomimetic model enabling quantitative description of the human breast tumor microenvironment.
Berger Fridman I; Kostas J; Gregus M; Ray S; Sullivan MR; Ivanov AR; Cohen S; Konry T
Acta Biomater; 2021 Sep; 132():473-488. PubMed ID: 34153511
[TBL] [Abstract][Full Text] [Related]
40. The Tumor Microenvironment: Signal Transduction.
Zhang X; Ma H; Gao Y; Liang Y; Du Y; Hao S; Ni T
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
